Chikungunya vaccine development: progress, problem and opportunity
Article Sidebar
Main Article Content
Abstract
Chikungunya vaccine development: progress, problem and opportunity
Chikungunya (CHIKV) is an arboviral disease transmitted by Aedes mosquitoes. The recent resurgence of CHIKV in Thailand is a matter of great public health concern. Despite the fact that CHIKV resurgence is associated with epidemic, no approved licensed vaccine is currently available. A formalin inactivated CHIKV vaccine revealed absence of untoward reactions or side effects and the acceptable immunogenic response in volunteers attested to the safety and immunogenicity of this vaccine. An attenuated CHIKV virus clone was developed for production of a live vaccine for human use. Vaccine (pilot lot production) elicited safety and immunogenicity of this vaccine in phase I and II studies in healthy adult volunteers. This live vaccine was safe, produced well tolerated side effects, and was highly immunogenic. Among the various vaccine approached, an attenuated live virus to be chosen should contain the gene for a broadly cross reacting protective antigen.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The opinions and content expressed in the articles are solely those of the individual authors and do not necessarily reflect the views of the journal or the authors’ affiliated institutions. Authors are fully responsible for the accuracy and correctness of their work.
Any reuse, reproduction, or redistribution of the articles, content, data, or images in other forms requires prior written permission from the Division of Vector Borne Diseases.
